Support Democrats’ Right to Speak Freely and Make Damn Fools of Themselves
Comedy Always Evolves, and Colbert Almost Killed It
John Brennan Plays the 'Nazi Card' While FBI Turns Up the Heat
Remember the McCloskeys? The Government Finally Gave Back What it Stole From Them.
The VP Harris Post-Mortem on Stephen Colbert (Yes, Kamala, the System Worked)
Trump’s Tariff Triumph
The Biggest Losetit
It’s Time for Independence for Biafra Free From Nigerian Control
Democrats Are in Disastrous Shape As Midterms Loom
Has Pressure on Advertisers to Leave X Hurt the Right’s Only Major Free...
Understanding Transgender Surgery
Kash Patel Uncovers Burn Bags and Buried Truths, Deep State Scrambles to Hide...
Democrat Calls Lawbreakers 'Long-Term Residents' in Stunning Display of Border Amnesia
America First, Big Pharma Last: Trump Orders Drug Prices Slashed to Lowest Global...
California Homeowners Take Up Arms as Crime Surges Under Newsom, Bass
Tipsheet

The FDA Just Approved This Surprising Standalone Treatment for Depression

AP Photo/Andrew Harnik, File

On Tuesday, the U.S. Food and Drug Administration (FDA) approved Johnson & Johnson’s nasal spray to be used alone in adults with major depressive disorder. 

Advertisement

The spray, called Spravato, is now the first-ever standalone therapy for treatment-resistant depression. This is when trying at least two standard treatments does little to nothing to improve depression symptoms in a patient.

According to CNBC, Spravato was cleared in the U.S. to use together with an oral antidepressant for both treatment-resistant depression and for people with major depressive disorder who are experiencing thoughts of suicide or harm. 

“We want to recognize that this is a medicine that treats a disease that [when] left untreated, depression is potentially fatal,” Bill Martin, J&J’s global therapeutic area head of neuroscience, said in an interview with the outlet.

Advertisement

Reportedly, about one-third of the estimated 21 million U.S. adults with major depression battle symptoms don’t respond to treatment.

“For the first time ever, we now have an option that gives patients freedom,” Dr. Gregory Mattingly, a physician and president of the Midwest Research Group who was involved in Spravato’s original clinical trials, said. 

Mattingly said patients can now choose to take Spravato with or without an oral antidepressant, especially if those pills aren’t improving their symptoms and are causing undesirable side effects.

The approval of Spravato was based on a phase four trial that showed that Spravato alone improved depressive symptoms beginning about 24 hours after treatment and lasting through at least one month. The drug first entered the US market in 2019.

Join the conversation as a VIP Member

Recommended

Trending on Townhall Videos

Advertisement
Advertisement
Advertisement